Difference between revisions of "Derache A, et al, Clin. Infect. Dis. (2019), cited as Ref 37 in DOI: 10.3390/v12020211 (Q10116)"
Jump to navigation
Jump to search
(Created claim: title (P93): Impact of Next-generation Sequencing Defined Human Immunodeficiency Virus Pretreatment Drug Resistance on Virological Outcomes in the ANRS 12249 Treatment-as-Prevention Trial, #quickstatements; #temporary...) |
(Added reference to claim: title (P93): Impact of Next-generation Sequencing Defined Human Immunodeficiency Virus Pretreatment Drug Resistance on Virological Outcomes in the ANRS 12249 Treatment-as-Prevention Trial, #quickstatements; #temporary_b...) |
||
| Property / title: Impact of Next-generation Sequencing Defined Human Immunodeficiency Virus Pretreatment Drug Resistance on Virological Outcomes in the ANRS 12249 Treatment-as-Prevention Trial (English) / reference | |||
| + | |||
Revision as of 19:43, 25 May 2020
Cited in: "Current Trends in Diagnostics of Viral Infections of Unknown Etiology" Viruses; 2020 Feb 14 ; 12 (2)
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Derache A, et al, Clin. Infect. Dis. (2019), cited as Ref 37 in DOI: 10.3390/v12020211
|
Cited in: "Current Trends in Diagnostics of Viral Infections of Unknown Etiology" Viruses; 2020 Feb 14 ; 12 (2)
|
Statements
Impact of Next-generation Sequencing Defined Human Immunodeficiency Virus Pretreatment Drug Resistance on Virological Outcomes in the ANRS 12249 Treatment-as-Prevention Trial (English)
